CPC G01N 33/57438 (2013.01) [A61K 31/7048 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/57419 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/918 (2013.01); G01N 2800/52 (2013.01)] | 5 Claims |
1. A method of stratifying and treating a patient suffering from biliary tract cancer (BTC), the method comprising the steps of
a) providing a BTC tumor sample of the patient,
b) determining the expression of carboxylesterase 2 (CES2) in the BTC tumor sample, wherein a lack of expression of CES2 in the BTC tumor sample indicates the risk of a patient that a treatment with an ester prodrug of a chemotherapeutic agent will not lead to a treatment success, and wherein the expression of CES2 in the BTC tumor sample indicates that a treatment with an ester prodrug of a chemotherapeutic agent will lead to a treatment success, and
c) (i) treating the patient whose BTC tumor sample is determined to express CES2 with the ester prodrug of a chemotherapeutic, or
(ii) treating the patient whose BTC tumor sample lacks CES2 expression with a treatment regimen that comprises a treatment that is different from the ester prodrug of a chemotherapeutic agent.
|